Crystal form and salt form of pyridoimidazole compound and preparation method therefor
AssigneeGuangdong Raynovent Biotech Co., Ltd.
InventorsJian Xiong, Xiaoxin Chen, Jingjing Wang, Zhuowei Liu, Kevin X Chen, Chengwu Liu, Cheng Xie, Chaofeng Long, Peng Li, Jian Li, Shuhui Chen
Life of this patent
Estimating the term…
Abstract
Disclosed are a crystal form and a salt form of a pyrazolopridine compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.
Claims25
A crystal form A or B of a compound of Formula (I),
- wherein n is selected from 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 4,
- wherein the crystal form A has an X-ray powder diffraction pattern (XRPD) with characteristic diffraction peaks at 2θ angles of 6.61±0.2°, 9.27±0.2°, 14.66±0.2°,
- wherein the crystal form B has an X-ray powder diffraction pattern (XRPD) with characteristic diffraction peaks at 2θ angles of 7.14±0.2°, 11.19±0.2°, 22.39±0.2°.
A compound of Formula (II) as represented by the following formula, or a crystal form C or D thereof:
- wherein,
- n2 is selected from 1;
- m2 is selected from 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 4;
- the crystal form C of the compound of Formula (II) has an X-ray powder diffraction (XRPD) pattern with characteristic diffraction peaks at 2θ angles of 8.00±0.2°, 15.06±0.2°, 15.84±0.2°;
- the crystal form D of the compound of Formula (II) has an X-ray powder diffraction (XRPD) pattern with characteristic diffraction peaks at 2θ angles of 6.96±0.2°, 10.31±0.2°, 14.95±0.2°.
A Compound 3 represented by the following formula, or a crystal form E thereof,
- wherein the crystal form E of Compound 3 has an X-ray powder diffraction (XRPD) pattern with characteristic diffraction peaks at 2θ angles of 8.10±0.2°, 9.60±0.2°, 22.97±0.2°.
A compound of Formula (III) as represented by the following formula, or a crystal form F or G thereof:
- wherein,
- n3 is selected from 1;
- m3 is selected from 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 4;
- wherein the crystal form F of the compound of Formula (III) has an X-ray powder diffraction (XRPD) pattern with characteristic diffraction peaks at 2θ angles of 6.47±0.2°, 9.11±0.2°, 9.90±0.2°;
- wherein the crystal form G of the compound of Formula (III) has an X-ray powder diffraction (XRPD) pattern with characteristic diffraction peaks at 2θ angles of 6.23±0.2°, 7.20±0.2°, 14.30±0.2°.
A compound of Formula (IV) as represented by the following formula, or a crystal form H, K, I or J thereof:
- wherein,
- n4 is selected from 1;
- m4 is selected from 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 4;
- wherein the crystal form H of the compound of Formula (IV) has an X-ray powder diffraction (XRPD) pattern with characteristic diffraction peaks at 2θ angles of 4.71±0.2°, 5.56±0.2°, 18.16±0.2°;
- wherein the crystal form K of the compound of Formula (IV) has an XRPD pattern with characteristic diffraction peaks at 2θ angles of 4.83±0.2°, 7.39±0.2°, 14.80±0.2°;
- wherein the crystal form I of the compound of Formula (IV) has an XRPD pattern with characteristic diffraction peaks at 2θ angles of 4.89±0.2°, 6.19±0.2°, 7.45±0.2°;
- wherein the crystal form J of the compound of Formula (IV) has an XRPD pattern with characteristic diffraction peaks at 2θ angles of 4.97±0.2°, 16.33±0.2°, 23.92±0.2°.
A compound of Formula (V) represented by the following formula, or a crystal form L thereof:
- wherein,
- n5 is selected from 0.5 and 1;
- m5 is selected from 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 4;
- wherein the crystal form L of the compound of Formula (V) has an X-ray powder diffraction (XRPD) pattern with characteristic diffraction peaks at 2θ angles of 10.39±0.2°, 18.04±0.2°, 20.31±0.2°.
Dependencies are inferred from the claim text.